Table 2.

Adverse events (safety population)

System organ class Preferred term	Biosimilar ranibizumab (N = 126) N (%) e
Total events	16 (12.70%) 19
Eye disorder	6 (4.76%) 6
Corneal edema	1 (0.79%) 1
Dry eye	1 (0.79%) 1
Eye pruritus	2 (1.59%) 2
Iridocyclitis	1 (0.79%) 1
Ocular hyperaemia	1 (0.79%) 1
General disorders and administration site conditions	6 (4.76%) 6
Death	1 (0.79%) 1
Pyrexia	5 (3.97%) 5
Infections and infestations	1 (0.79%) 1
Nasopharyngitis	1 (0.79%) 1
Investigations	4 (3.17%) 5
Raised blood pressure	1 (0.79%) 1
Increase in intraocular pressure	3 (2.38%) 4
Nervous system disorders	1 (0.79%) 1
Headache	1 (0.79%) 1

N Number of patients, e Number of events

Adverse events were categorized using MedDRA Version 20.1